| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Chi-Un Pa. Role of the cholinesterase inhibitors in the treatment of schizophrenia. Expert opinion on investigational drugs. vol 22. issue 3. 2013-07-30. PMID:23330829. |
in fact, according to recent clinical trials, newer antipsychotics, which have little effect on cholinergic receptors but potent antagonistic effects on the serotonin-7 receptor (5-ht(7); e.g., lurasidone), may ameliorate cognitive defects in patients with schizophrenia. |
2013-07-30 |
2023-08-12 |
Not clear |
| Mark Sanfor. Lurasidone : in the treatment of schizophrenia. CNS drugs. vol 27. issue 1. 2013-07-03. PMID:23264146. |
lurasidone : in the treatment of schizophrenia. |
2013-07-03 |
2023-08-12 |
Not clear |
| Mark Sanfor. Lurasidone : in the treatment of schizophrenia. CNS drugs. vol 27. issue 1. 2013-07-03. PMID:23264146. |
this review focuses on the efficacy and tolerability of lurasidone, which is approved in the usa, puerto rico and canada for the treatment of schizophrenia. |
2013-07-03 |
2023-08-12 |
Not clear |
| Mark Sanfor. Lurasidone : in the treatment of schizophrenia. CNS drugs. vol 27. issue 1. 2013-07-03. PMID:23264146. |
in two placebo-controlled, phase ii trials, lurasidone 40-120 mg/day was efficacious in reducing the acute symptoms of schizophrenia. |
2013-07-03 |
2023-08-12 |
Not clear |
| Mark Sanfor. Lurasidone : in the treatment of schizophrenia. CNS drugs. vol 27. issue 1. 2013-07-03. PMID:23264146. |
in two placebo- and active treatment-controlled, phase iii trials, lurasidone at dosages of 40-160 mg/day, olanzapine 15 mg/day and quetiapine extended-release (xr) 600 mg/day were efficacious in reducing the symptoms of schizophrenia. |
2013-07-03 |
2023-08-12 |
Not clear |
| Masaaki Ogasa, Tatsuya Kimura, Mitsutaka Nakamura, John Guarin. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacology. vol 225. issue 3. 2013-06-21. PMID:22903391. |
lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. |
2013-06-21 |
2023-08-12 |
Not clear |
| William V Bob. Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert review of clinical pharmacology. vol 6. issue 1. 2013-05-14. PMID:23272794. |
asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. |
2013-05-14 |
2023-08-12 |
Not clear |
| William V Bob. Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert review of clinical pharmacology. vol 6. issue 1. 2013-05-14. PMID:23272794. |
this article reviews the pharmacological profile and published efficacy and tolerability/safety data of iloperidone, asenapine and lurasidone, the most recent atypical antipsychotics to be approved in the usa for the treatment of schizophrenia. |
2013-05-14 |
2023-08-12 |
Not clear |
| Joseph P McEvoy, Leslie Citrome, David Hernandez, Josephine Cucchiaro, Jay Hsu, Andrei Pikalov, Antony Loebe. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study. The Journal of clinical psychiatry. vol 74. issue 2. 2013-04-29. PMID:23473350. |
effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study. |
2013-04-29 |
2023-08-12 |
Not clear |
| Marc De Hert, Weiping Yu, Johan Detraux, Kim Sweers, Ruud van Winkel, Christoph U Correl. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS drugs. vol 26. issue 9. 2013-01-14. PMID:22900950. |
body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. |
2013-01-14 |
2023-08-12 |
Not clear |
| Vineeta Risbood, Jennifer R Lee, Jennifer Roche-Desilets, Matthew A Fulle. Lurasidone: an atypical antipsychotic for schizophrenia. The Annals of pharmacotherapy. vol 46. issue 7-8. 2012-12-26. PMID:22828971. |
lurasidone: an atypical antipsychotic for schizophrenia. |
2012-12-26 |
2023-08-12 |
Not clear |
| Roger S McIntyre, Danielle S Cha, Mohammad Alsuwaidan, Diane McIntosh, Alissa M Powell, Jeanette M Jerrel. A review of published evidence reporting on the efficacy and pharmacology of lurasidone. Expert opinion on pharmacotherapy. vol 13. issue 11. 2012-11-07. PMID:22559286. |
lurasidone is a benzisothiazol derivative, approved by the us food and drug administration for the acute treatment of adults with schizophrenia. |
2012-11-07 |
2023-08-12 |
Not clear |
| Roger S McIntyre, Danielle S Cha, Mohammad Alsuwaidan, Diane McIntosh, Alissa M Powell, Jeanette M Jerrel. A review of published evidence reporting on the efficacy and pharmacology of lurasidone. Expert opinion on pharmacotherapy. vol 13. issue 11. 2012-11-07. PMID:22559286. |
controlled trials are currently underway to evaluate lurasidone's efficacy in bipolar depression as well as its procognitive effects in individuals with schizophrenia. |
2012-11-07 |
2023-08-12 |
Not clear |
| Leslie Citrom. Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed? Clinical schizophrenia & related psychoses. vol 6. issue 2. 2012-09-20. PMID:22776634. |
lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed? |
2012-09-20 |
2023-08-12 |
Not clear |
| Leslie Citrom. Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed? Clinical schizophrenia & related psychoses. vol 6. issue 2. 2012-09-20. PMID:22776634. |
to describe the efficacy, safety and tolerability of lurasidone for the acute treatment of schizophrenia using the metrics number needed to treat (nnt) and number needed to harm (nnh). |
2012-09-20 |
2023-08-12 |
Not clear |
| Norio Yasui-Furukor. Update on the development of lurasidone as a treatment for patients with acute schizophrenia. Drug design, development and therapy. vol 6. 2012-08-27. PMID:22675261. |
update on the development of lurasidone as a treatment for patients with acute schizophrenia. |
2012-08-27 |
2023-08-12 |
human |
| Norio Yasui-Furukor. Update on the development of lurasidone as a treatment for patients with acute schizophrenia. Drug design, development and therapy. vol 6. 2012-08-27. PMID:22675261. |
lurasidone is a novel benzisothiazole antipsychotic drug for the treatment of schizophrenia. |
2012-08-27 |
2023-08-12 |
human |
| Norio Yasui-Furukor. Update on the development of lurasidone as a treatment for patients with acute schizophrenia. Drug design, development and therapy. vol 6. 2012-08-27. PMID:22675261. |
these results suggest that lurasidone treatment may be a novel approach for the prevention of the development of cognitive impairment in individuals who are at risk for schizophrenia or related disorders involving cognitive impairment. |
2012-08-27 |
2023-08-12 |
human |
| Silvio Caccia, Luca Pasina, Alessandro Nobil. Critical appraisal of lurasidone in the management of schizophrenia. Neuropsychiatric disease and treatment. vol 8. 2012-08-23. PMID:22570547. |
critical appraisal of lurasidone in the management of schizophrenia. |
2012-08-23 |
2023-08-12 |
Not clear |
| Mei Huang, Masakuni Horiguchi, Anna R Felix, Herbert Y Meltze. 5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux. Neuroreport. vol 23. issue 7. 2012-08-02. PMID:22415605. |
these findings suggest that the effects of lurasidone on the prefrontal cortex and hippocampus, da efflux are dependent, at least partially, on its 5-ht1a agonist and 5-ht7 antagonist properties and may contribute to its efficacy to reverse the effects of subchronic phencyclidine treatment and improve schizophrenia. |
2012-08-02 |
2023-08-12 |
rat |